https://www.selleckchem.com/pr....oducts/nvp-dky709.ht
The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated with modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated. We retrospectively evaluated the data of EGFR mutated NSCLC patients with bone metastases treated with TKIs in 12 Italian centers from 2014 to 2019, with the primary aim to explore type and frequency of SREs. Seventy-seven out of 274 patients enrolled (28%) developed at least one major SRE 55/274 (20%) bone frac
Like
Comment
Share
